US Bancorp DE decreased its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 26.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 119,287 shares of the company's stock after selling 43,819 shares during the quarter. US Bancorp DE owned 0.08% of Adaptive Biotechnologies worth $715,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Ashton Thomas Securities LLC bought a new position in Adaptive Biotechnologies in the 3rd quarter valued at approximately $34,000. KBC Group NV bought a new stake in Adaptive Biotechnologies in the 4th quarter worth about $50,000. Townsquare Capital LLC bought a new position in Adaptive Biotechnologies during the 3rd quarter valued at about $56,000. GAMMA Investing LLC bought a new position in Adaptive Biotechnologies during the fourth quarter valued at approximately $59,000. Finally, Centiva Capital LP purchased a new stake in Adaptive Biotechnologies during the 3rd quarter valued at $80,000. Institutional investors own 99.17% of the company's stock.
Insider Transactions at Adaptive Biotechnologies
In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 211,160 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $8.50, for a total value of $1,794,860.00. Following the sale, the chief executive officer now owns 2,576,701 shares in the company, valued at $21,901,958.50. The trade was a 7.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Francis Lo sold 20,875 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $6.99, for a total transaction of $145,916.25. Following the transaction, the insider now directly owns 332,846 shares of the company's stock, valued at $2,326,593.54. This trade represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 755,903 shares of company stock valued at $6,025,342 over the last 90 days. Company insiders own 6.20% of the company's stock.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on ADPT shares. The Goldman Sachs Group raised their price target on Adaptive Biotechnologies from $5.50 to $7.50 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. BTIG Research boosted their price target on Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. Piper Sandler reiterated an "overweight" rating and issued a $11.00 price objective (up previously from $7.00) on shares of Adaptive Biotechnologies in a research note on Thursday, February 20th. Finally, Scotiabank raised their price objective on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $9.10.
Read Our Latest Stock Analysis on Adaptive Biotechnologies
Adaptive Biotechnologies Stock Down 6.6 %
NASDAQ:ADPT traded down $0.50 during mid-day trading on Thursday, hitting $7.12. 215,746 shares of the company traded hands, compared to its average volume of 1,695,556. The stock's fifty day moving average price is $7.63 and its 200-day moving average price is $6.09. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -6.55 and a beta of 1.53. Adaptive Biotechnologies Co. has a one year low of $2.28 and a one year high of $8.95.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.04. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. During the same period in the prior year, the company posted ($0.30) earnings per share. Equities analysts predict that Adaptive Biotechnologies Co. will post -0.92 EPS for the current year.
Adaptive Biotechnologies Profile
(
Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Featured Articles
Before you consider Adaptive Biotechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.
While Adaptive Biotechnologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
